转录组
肝细胞癌
生物
细胞色素P450
肝癌
癌症研究
癌变
代谢组
癌症
内科学
基因表达
基因
生物信息学
内分泌学
代谢组学
医学
遗传学
新陈代谢
作者
Fubo Ji,Jianjuan Zhang,Niya Liu,Yuanzhuo Gu,Yan Zhang,Peipei Huang,Nachuan Zhang,Shengda Lin,Ran Pan,Zhuo-Xian Meng,Xin‐Hua Feng,Stephanie Roessler,Xin Zheng,Junfang Ji
出处
期刊:Gut
[BMJ]
日期:2022-01-07
卷期号:71 (11): 2313-2324
被引量:31
标识
DOI:10.1136/gutjnl-2021-326050
摘要
Objects The incidence of hepatocellular carcinoma (HCC) shows an obvious male dominance in rodents and humans. We aimed to identify the key autosomal liver-specific sex-related genes and investigate their roles in hepatocarcinogenesis. Design Two HCC cohorts (n=551) with available transcriptome and metabolome data were used. Class comparisons of omics data and ingenuity pathway analysis were performed to explore sex-related molecules and their associated functions. Functional assays were employed to investigate roles of the key candidates, including cellular assays, molecular assays and multiple orthotopic HCC mouse models. Results A global comparison of multiple omics data revealed 861 sex-related molecules in non-tumour liver tissues between female and male HCC patients, which denoted a significant suppression of cancer-related diseases and functions in female liver than male. A member of cytochrome P450 family, CYP39A1, was one of the top liver-specific candidates with significantly higher levels in female vs male liver. In HCC tumours, CYP39A1 expression was dramatically reduced in over 90% HCC patients. Exogenous CYP39A1 significantly blocked tumour formation in both female and male mice and partially reduced the sex disparity of hepatocarcinogenesis. The HCC suppressor role of CYP39A1 did not rely on its known P450 enzyme activity but its C-terminal region, by which CYP39A1 impeded the transcriptional activation activity of c-Myc, leading to a significant inhibition of hepatocarcinogenesis. Conclusions The liver-specific CYP39A1 with female-preferential expression was a strong suppressor of HCC development. Strategies to up-regulate CYP39A1 might be promising methods for HCC treatment in both women and men in future.
科研通智能强力驱动
Strongly Powered by AbleSci AI